Joseph S. McCracken - 27 Aug 2021 Form 4 Insider Report for Kindred Biosciences, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 27 Aug 2021
Net transaction value: -$233,285
SEC form: 4
Accepted by SEC: 30 Aug 2021, 14:55:59 UTC
Prior SEC filing: 13 Aug 2021
Next SEC filing: 14 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Joseph S. McCracken

Key filing fact

Joseph S. McCracken filed Form 4 for Kindred Biosciences, Inc. on 30 Aug 2021.

Key facts

This page summarizes Joseph S. McCracken's Form 4 filing for Kindred Biosciences, Inc..
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 30 Aug 2021, 14:55.

Change

Previous filing in this sequence was filed on 13 Aug 2021.
Current net transaction value: -$233,285.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KIN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -41,890
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,890
Exercise price: $9.65
Footnotes: F1

KIN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -10,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $11.00
Footnotes: F2

KIN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -48,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,500
Exercise price: $9.91
Footnotes: F3

KIN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -48,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,500
Exercise price: $9.84
Footnotes: F4

KIN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $233,285
Shares: -48,500
Change %: -100%
Price: $4.81
Shares after: 0
Date: 27 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,500
Exercise price: $4.44
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Joseph S. McCracken is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for no consideration.

Footnote F2

This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

Footnote F3

This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

Footnote F4

This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

Footnote F5

This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $233,285.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.